Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-01EMA Authorised: Keytruda (pembrolizumab) — Merck Sharp & Dohme B.V.
EMA authorises Keytruda (pembrolizumab) for multiple cancer indications, including melanoma, Hodgkin disease, renal cell carcinoma, non-smal…
-
CLINICAL_TRIALS trial_result · 2026-06-29Clinical Trial Update: A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer [Phase 3]
Phase 3 trial comparing SB27 with Keytruda in metastatic non-squamous non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2026-06-26Clinical Trial Update: Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) [Phase 3]
Phase 3 trial evaluating pembrolizumab/vibostolimab with concurrent chemoradiotherapy, followed by pembrolizumab/vibostolimab versus durvalu…
-
CLINICAL_TRIALS trial_result · 2026-06-26Clinical Trial Update: Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery [Phase 3]
Phase 3 trial investigating perioperative bronchodilator use in COPD patients undergoing lung cancer surgery.
-
CLINICAL_TRIALS trial_result · 2026-06-25Clinical Trial Results: Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) [Phase 3]
Phase 3 trial results comparing REGN 2810 to platinum-based chemotherapy in metastatic non-small cell lung cancer have been completed with r…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-06-25Clinical Trial Update: Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer [Phase 3]
Phase 3 trial comparing JDQ443 with docetaxel in locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer is active but no…
-
CLINICAL_TRIALS trial_result · 2026-06-16Clinical Trial Update: Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC [Phase 3]
Phase III study of SY-5007, a RET inhibitor, in RET fusion-positive non-small cell lung cancer is active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-06-12Clinical Trial Results: Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation [Phase 2]
Phase 2 trial results for poziotinib in non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations have been posted after term…
-
CLINICAL_TRIALS trial_result · 2026-06-11Clinical Trial Results: Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)
A completed secondary data collection study assessing safety and efficacy of VIZIMPRO tablets under Japanese medical practice for EGFR mutat…
-
CLINICAL_TRIALS trial_result · 2026-06-11Clinical Trial Results: NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC [Phase 2]
Phase 2 trial results of NT-I7 in combination with atezolizumab in previously untreated, PD-L1-expressing locally advanced or metastatic non…
-
EMA approval · 2026-06-10EMA Authorised: Vargatef (nintedanib) — Boehringer Ingelheim International GmbH
Approval of Vargatef (nintedanib) by EMA for non-small cell lung carcinoma.
-
CLINICAL_TRIALS trial_result · 2026-06-10Clinical Trial Results: A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy [Phase 3]
Phase 3 study evaluating tiragolumab plus atezolizumab versus placebo plus atezolizumab in completely resected NSCLC after adjuvant platinum…
-
CLINICAL_TRIALS trial_result · 2026-06-09Clinical Trial Results: Precision-exercise-prescription for Lung Cancer Patients Undergoing Surgery: The PEP Study [Phase 3]
Phase 3 trial evaluating precision-exercise prescription for lung cancer patients undergoing surgery has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2026-06-09Clinical Trial Update: Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) [Phase 3]
Phase 3 trial comparing sacituzumab deruxtecan (MK-2870) against pemetrexed plus carboplatin in EGFR-mutated, advanced nonsquamous NSCLC aft…
-
CLINICAL_TRIALS trial_result · 2026-06-09Clinical Trial Update: Precision-exercise-prescription for Lung Cancer Patients Undergoing Surgery: The PEP Study [Phase 3]
Phase 3 trial evaluating precision exercise prescription for lung cancer patients undergoing surgery has completed; results posted.
-
EMA approval · 2026-06-08EMA Authorised: Alecensa (alectinib hydrochloride) — Roche Registration GmbH
The EMA authorised Alecensa (alectinib hydrochloride) for non-small cell lung carcinoma, with Roche Registration GmbH as the MAH.
-
CLINICAL_TRIALS trial_result · 2026-06-08Clinical Trial Update: Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer [Phase 3]
Phase 3 trial evaluating JDQ443 versus docetaxel in locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2026-06-08Clinical Trial Update: Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer [Phase 3]
Phase 3 trial comparing photon therapy versus proton therapy for various stages of non-small cell lung cancer is active/not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Update: A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer [Phase 3]
Phase 3 trial evaluating osimertinib with or without chemotherapy versus chemotherapy alone as neoadjuvant therapy for EGFRm-positive resect…
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) [Phase 2, Phase 3]
A combined Phase 2/Phase 3 trial evaluating multiple targeted therapies for non-small cell lung cancer is active but not currently recruitin…
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Results: A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) [Phase 3]
Phase 3 trial comparing atezolizumab plus tiragolumab versus durvalumab in locally advanced, unresectable stage III non-small cell lung canc…
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Results: A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer [Phase 2, Phase 3]
Phase 2/3 trial evaluating tiragolumab with atezolizumab plus pemetrexed and platinum vs pembrolizumab plus pemetrexed and platinum in untre…
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Update: A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) [Phase 3]
Phase 3 trial comparing atezolizumab plus tiragolumab versus durvalumab in locally advanced, unresectable stage III non-small cell lung canc…
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Update: A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer [Phase 2, Phase 3]
Phase 2/3 trial evaluating tiragolumab with atezolizumab-based PEM/CAR pembrolizumab-based therapy in previously untreated advanced non-squa…
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Update: Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC [Phase 3]
Phase 3 trial update evaluating the effect of time-of-day immunochemotherapy on progression-free survival in non-small cell lung cancer.